



CONVERSATION RECORD

NAME OF PERSON(S) CONTACTED OR IN CONTACT WITH YOU Cheryl Culver Schultz		DATE OF CONTACT 04/18/2016	TYPE OF CONVERSATION	
E-MAIL ADDRESS		TELEPHONE NUMBER (248) 551-0548	<input type="checkbox"/> E-MAIL	<input type="checkbox"/> INCOMING
ORGANIZATION Beaumont Hospital		DOCKET NUMBER(S) 030-02006	<input checked="" type="checkbox"/> TELEPHONE	<input type="checkbox"/> OUTGOING
LICENSE NUMBER(S) 21-01333-01		CONTROL NUMBER(S) N/A		

SUBJECT
Letter dated 3/18/16 requesting an amendment to add a proton-generating cyclotron for patient treatment

SUMMARY AND ACTION REQUIRED (IF ANY)

I contacted Ms. Schultz to advise her that the NRC does not have jurisdiction over cyclotrons, or similar type devices, e.g., LINACS, which are used for patient treatment. The NRC only regulates materials that are intentionally made using a cyclotron or other particle accelerator where those materials are used for commercial, research, or medical purposes.

I generally explained the following: The EAct expanded the definition of Byproduct material by: (1) Adding any discrete source of radium-226 that is produced, extracted, or converted after extraction, before, on, or after the date of enactment of the EAct for use for a commercial, medical, or research activity; or any material that has been made radioactive by use of a particle accelerator and is produced, extracted, or converted after extraction, before, on, or after the date of enactment of the EAct for use for a commercial, medical, or research activity (Section 11e.(3) of the AEA); and (2) adding any discrete source of naturally occurring radioactive material.

For example, we regulate radionuclides that are made by a cyclotron, e.g., fluorine-18, where the material is used for medical imaging. NRC would also regulate the incidentally activated products when it regulates the material that is produced by the cyclotron.

Cheryl confirmed that their use of the proton generating cyclotron referenced in her letter is only for patient treatment and not to produce radioactive materials for commercial, research, or medical use.

NAME OF PERSON DOCUMENTING CONVERSATION Kevin Null	
SIGNATURE 	DATE OF SIGNATURE 04/18/2016 4/21/16